# Quantitative Flow Cytometry—Medical Applications with a Focus on Blood Platelets

**Authors:** Philippe Poncelet, Thomas Lecompte, Anne Bauters, François Mullier

PMC · DOI: 10.3390/ijms27041976 · International Journal of Molecular Sciences · 2026-02-19

## TL;DR

This review explains how quantitative flow cytometry has evolved to measure cell-surface molecules, especially on blood platelets, and its medical applications.

## Contribution

The paper provides a comprehensive overview of the evolution and current state of quantitative flow cytometry in platelet research and diagnostics.

## Key findings

- Quantitative flow cytometry has advanced to measure platelet surface antigens with calibration beads and immunofluorescence.
- Commercial kits for platelet antigen quantitation are available and can aid in diagnosing platelet disorders.
- Platelet antigen quantification is emerging as a tool for monitoring targeted therapies.

## Abstract

Flow cytometry, measuring light signals, can be used as a quantitative tool to appreciate the numbers of cell-surface molecules targeted with monoclonal antibodies, among other applications. This has been extensively used for blood cells and especially platelets. This review describes how techniques have evolved over time since the first developments of quantitative flow cytometry at the end of the 20th century. Technological issues are first described, applicable to all types of cells/molecules and largely relying on calibration beads with direct or, preferably, indirect immunofluorescence. The platelet field is then addressed with specific tools devoted to surface antigen quantitation. The array of commercially available kits is provided with their specificity. A panorama of platelet antigens quantified that can be used in the diagnosis workout of platelet disorders is then provided, accompanied by a reminder of the impressive stability of marker expression in normal individuals. Variations are then considered in the light of aging or genetic polymorphisms. Finally, the upcoming use of platelet antigen quantification as a monitoring tool for emerging targeted therapies is evoked. All in all, this review provides a comprehensive story of the evolution of the still too marginally used cell antigen quantification.

## Full-text entities

- **Genes:** PRNP (prion protein (Kanno blood group)) [NCBI Gene 5621] {aka ASCR, AltPrP, CD230, CJD, GSS, KURU}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, GP1BA (glycoprotein Ib platelet subunit alpha) [NCBI Gene 2811] {aka BDPLT1, BDPLT3, BSS, CD42B, CD42b-alpha, DBPLT3}, ITGB3 (integrin subunit beta 3) [NCBI Gene 3690] {aka BDPLT16, BDPLT2, BDPLT24, CD61, FMAIT1, GP3A}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, TRAP [NCBI Gene 100187907], PTPRJ (protein tyrosine phosphatase receptor type J) [NCBI Gene 5795] {aka CD148, DEP1, HPTP eta, HPTPeta, R-PTP-ETA, R-PTP-J}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, Itga2 (integrin alpha 2) [NCBI Gene 16398] {aka CD49B, DX5, GPIa}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, Clec1b (C-type lectin domain family 1, member b) [NCBI Gene 56760] {aka 1810061I13Rik, Clec-2, Clec2}, ETV6 (ETS variant transcription factor 6) [NCBI Gene 2120] {aka TEL, TEL/ABL, THC5}, GP6 (glycoprotein VI platelet) [NCBI Gene 51206] {aka BDPLT11, GPIV, GPVI}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, HPSE (heparanase) [NCBI Gene 10855] {aka HPA, HPA1, HPR1, HPSE1, HSE1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, Gp6 (glycoprotein 6 platelet) [NCBI Gene 243816] {aka 9830166G18Rik, Gm469, Gpvi}, GFI1B (growth factor independent 1B transcriptional repressor) [NCBI Gene 8328] {aka BDPLT17, ZNF163B}, RNF130 (ring finger protein 130) [NCBI Gene 55819] {aka G1RP, G1RZFP, GOLIATH, GP}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, CD34 (CD34 molecule) [NCBI Gene 947], ITGA2B (integrin subunit alpha 2b) [NCBI Gene 3674] {aka BDPLT16, BDPLT2, CD41, CD41B, FMAIT2, GP2B}, FCGR2A (Fc gamma receptor IIa) [NCBI Gene 2212] {aka CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1}, NAAA (N-acylethanolamine acid amidase) [NCBI Gene 27163] {aka ASAHL, PLT}, Itga2b (integrin alpha 2b) [NCBI Gene 16399] {aka CD41, CD41B, GpIIb, alphaIIb}
- **Diseases:** IPD (MESH:C564352), acute coronary syndrome (MESH:D054058), leukemic (MESH:D007938), QFCM (MESH:D054318), GPS (MESH:D055652), arterial thrombosis (MESH:D002341), myeloproliferative disorders (MESH:D009196), injury to (MESH:D014947), rheumatoid arthritis (MESH:D001172), IPDs (MESH:D001791), retinal vein occlusion (MESH:D012170), thrombosis (MESH:D013927), APS (MESH:D016736), PTP (MESH:D065227), myocardial infarction (MESH:D009203), thrombocytopenia (MESH:D013921), ischemic stroke (MESH:D002544), inherited thrombocytopenia (MESH:C566060), FNAIT (MESH:D054098), bleeding (MESH:D006470), SLE (MESH:D008180), GT (MESH:D013915), genetic (MESH:D030342), hematological malignancy (MESH:D019337), BSS (MESH:D001606)
- **Chemicals:** phosphate (MESH:D010710), SFLLRN (MESH:C082835), MEFL (-), saline (MESH:D012965), polymer (MESH:D011108), FITC (MESH:D016650), EDTA (MESH:D004492), thiazole (MESH:D013844), Abciximab (MESH:D000077284), Aggrastat (MESH:D000077466), citrate (MESH:D019343), Integrilin (MESH:D000077542), ACT017 (MESH:C000711868), heparin (MESH:D006493)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** G873A, C807T, histidine (H) by an arginine (R) in position 131, L33P, G > A, A873

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940865/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940865/full.md

## References

86 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940865/full.md

---
Source: https://tomesphere.com/paper/PMC12940865